Pharmacological treatment of septic shock

Bibliography

• WHEELER AP, BERNARD GR: Treating patients with severe sepsis. N Engl. J. Med. (1999) 340:207–214.
   PubMed Web of Science ®Google Scholar
• OPAL SM, CROSS AS: Clinical trials for severe sepsis. Infect. Dis. Olin. North Am. (1999) 13(2):285–297.
   PubMed Web of Science ®Google Scholar
• RANGEL-FRAUSTO MS: The epidemiology of bacterial sepsis. Infect. Dis. Olin. North Am. (1999) 13(2):299–311.
   PubMed Web of Science ®Google Scholar
• RANGEL-FRAUSTO MS, PITTET D, COSTIGAN M, HWANG T, DAVIS CS, WENZEL RP: The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA (1995) 273:117–123.
   PubMed Web of Science ®Google Scholar
• HARDAWAY RM: A review of septic shock. Am. Sorg. (2000) 66:22–29.
   Google Scholar
• PARILLO JE (moderator): Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann. Intern. Merl. (1990) 113:227–242.
   PubMed Web of Science ®Google Scholar
• NATANSON C, DANNER RL, REILLY JM et al.: Antibiotics versus cardiovascular support in a canine model of human septic shock. Am. J. Physiol. (1990) 259:H1440–H1447.
   Google Scholar
• SHENEP JL, MORGAN KA: Kinetics of endotoxin release during, antibiotic therapy for experimental Gram-negative bacterial sepsis. J. Infect. Dis. (1984) 150:380–388.
   PubMed Web of Science ®Google Scholar
• LYNN WA, COHEN J: Adjunctive therapy for septic shock: A review of experimental approaches. Clin. Infect. Dis. (1995) 20:143
   PubMed Web of Science ®Google Scholar
• HELLMAN J, WARREN HS: Anti-endotoxin strategies. Infect. Dis. North Am. (1999) 13:371–386.
   PubMed Web of Science ®Google Scholar
• VUORIO R, VAARA M: The lipid A biosynthesis mutation of lpxA2 of Escherichia coli results in drastic antibi-otic supersusceptibility. Antimicrob. Agents Chemother. (1992) 36:826–829.
   PubMed Web of Science ®Google Scholar
• RAETZ CR. Bacterial endotoxins: extraordinary lipids that activate eukaryotic signal transduction. J. Bacteriol. (1993) 175:5745–5753.
   PubMed Web of Science ®Google Scholar
• KELLY TM, STACHULA SA, RAETZ CRH, ANDERSON MS:The firA gene of Escherichia coli encodes UDP-3-0- (R-3-hydroxymyristoy1)-glucosamine-N-acyltransferase. J. Biol. Chem. (1993) 268:19866–19874.
   PubMed Web of Science ®Google Scholar
• ONISHI HR, PELAK BA, GERCKENS LS et al.: Antibacterialagents that inhibit lipid A biosynthesis. Science (1996) 274:980–982.
   PubMed Web of Science ®Google Scholar
• GOLDMAN R, KOHLBRENNER W, LARETY P et al.: Antibacterial agents specifically inhibiting lipopoly-saccharide synthesis. Nature (1987) 329:162–164.
   PubMed Web of Science ®Google Scholar
• BONE RC, BALK RA, FEIN AM et al.: A second largecontrolled clinical trial of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomised, controlled trial. Grit. Care Med. (1995) 23:994–1006.
   PubMed Web of Science ®Google Scholar
• ZEIGLER EJ, FISHER JRCJ, SPRUNG CL eta].: Treatment of Gram-negative bacteremia in septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl. J. Med. (1991) 324:429–438.
   Google Scholar
• CROSS AS, OPAL SM: Therapeutic intervention in sepsis with antibody to endotoxin: is there a future? J. Endotoxin Res. (1994) 1:57–69.
   Google Scholar
• RIETSCHEL ET, BRADE H, HOLST 0 et al.: Bacterial endotoxin: chemical composition, biological recogni-tion, host response and immunological detoxifica-tion. Curr. Topics Microbiol. Immunol. (1996) 216:39–81.
   Google Scholar
• TONOLI M, DAVIES KA, NORSWORTHY PJ, COHEN J, WALPORT MJ: The antilipid A antibody HA-1A binds to rough Gram-negative bacteria, fixes complement and facilitates binding to erythrocyte CR1 (CD35). Exp. Immunol. (1993) 92:232–238.
   PubMed Web of Science ®Google Scholar
• ZIEGER EJ, EICHER CJ JR. SPRUNG CL et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomised double-blind, placebo-controlled trial. N Engl. J. Med. (1991) 324:429–436.
   PubMed Web of Science ®Google Scholar
• DI PADOVA FE, BARCLAY R, BRADE H et al: SDZ219-800: a chimeric broadly cross-reactive and cross-neutralising anticore LPS antibody. Circ. Shock (1993) 1 (Suppl.):47.
   Google Scholar
• STRUTZ F, HELLER G, KRASEMANN K, KRONE B, MULLER GA: Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome. Intensive Care Med. (1999) 25(5):435–444.
   PubMed Web of Science ®Google Scholar
• BHATTERCHARJEE AK, OPAL SM, PALARDY JE et al: Affinity purified E. coil' J5 LPS-specific IgG protects neutropenic rats against Gram-negative sepsis. J. Infect. Dis. (1994) 170: 622–629.
   Google Scholar
• BHATTERCHARJEE AK, OPAL SM, TAYLOR R et al.: A non-covalent complex vaccine prepared with detoxi-fied E. coli J5 LPS and Neisseria meningitidis group B outer membrane protein produces protective antibodies against Gram-negative bacteria. J. Infect. Dis. (1996) 173:1157–1162.
   Google Scholar
• DONTA ST, PEDUZZI P, CROSS AS et al.: Immunoprophy-laxis against Klebsiella and Pseudomonas aeruginosa infections. J. Infect. Dis. (1996) 174:537–543.
   PubMed Web of Science ®Google Scholar
• WURFEL MM, HAILMAN E, WRIGHT SD: Soluble CD14 acts as a shuttle in the neutralisation of lipopolysac-charide (LPS) by LPS-binding protein and reconsti-tuted high density lipoprotein. J. Exp. Med. (1995) 181:1743–1754.
   PubMed Web of Science ®Google Scholar
• PAJKRT D, DORAN JE, COSTER F et al.: Anti-inflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. (1996) 184:1601–1608.
   PubMed Web of Science ®Google Scholar
• LERCH PG, FORTSH V, HOLDER G et al.: Production and characterisation of a reconstituted high density lipoprotein (rHDL) for therapeutic application. Vox Sang. (1996) 71:155–164.
   PubMed Web of Science ®Google Scholar
• ZHANG GH, MANN DM, TSAI CM: Neutralisation of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect. Immun. (1999) 67:1353–1358.
   PubMed Web of Science ®Google Scholar
• LEE WJ, FARMER JL, HILTY M, KIM YB: The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets. Infect. Immun. (1998) 66:1421–1426.
   PubMed Web of Science ®Google Scholar
• OPAL SM, PALARDY JE, MARRA MN et al: Relative concentrations of endotoxin-binding proteins in body fluids during infection. Lancet (1994) 344:429–431.
   PubMed Web of Science ®Google Scholar
• LAMPING N, DETTMER R, SCHRODER NW et al.: LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J. Clin. Invest. (1998) 101:2056–2071.
   Web of Science ®Google Scholar
• LIN Y, LEACH WJ, AMMONS WS: Synergistic effect of a recombinant N-terminal fragment of bacteri-cidal/permeability-increasing protein and cefaman-dole in treatment of rabbit Gram-negative sepsis. Antimicrob. Agents Chemother. (1996) 40(1):65–69.
   PubMed Web of Science ®Google Scholar
• GIROIR B, CARROLL S, SCANNON P: Phase I/II trial of rBPI2 in children with severe meningococcemia [abstract no. 414]. Infectious Disease Society of America Annual Meeting, San Francisco, CA (1997).
   Google Scholar
• HIRATA M, SHIMOMURA Y, YOSHIDA M et al: Charac-terisation of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infect. Immun. (1994) 62:1421–1426.
   PubMed Web of Science ®Google Scholar
• SALADINO R, GARCOA C, THOMPSON C et al.: Efficacy of a, recombinant endotoxin neutralising protein in rabbits with Escherichia coli sepsis. Circ. Shock (1994) 42:104–110.
   PubMedGoogle Scholar
• DE HAAS CJ, VAN DER ZEE R, BENAISSA-TROUW B et al: Lipopolysaccharide (LPS)-binding synthetic peptides derived from serum amyloid P component neutralises LPS. Infect. Immun. (1999) 6:2790–2796.
   Google Scholar
• SCHIMKE J, MATHISON J, MORGIEWICZ J, ULEVITCH RJ: AntiCD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc. Natl. Acad. Sci. USA (1998) 95 (23):13875–13880.
   PubMed Web of Science ®Google Scholar
• HANASAWA L, TANI T, KODAMA M: New approach to endotoxic and septic shock by means of polymyxin B immobilized fibre. Surg. GynecoL Obstet. (1989) 168:323–331.
   PubMedGoogle Scholar
• AOKI H, KODAMA M, TANI T et al.: Treatment of sepsisby extracorporeal elimination of endotoxin using polymyxin B-immobilized fibre. Am. J. Surg. (1994) 167:412–417.
   PubMed Web of Science ®Google Scholar
• SATO T, ORLOWSKI JP, ZBOROWSKI M: Experimental study of extracorporeal perfusion for septic shock. ASAIO J (1993) 39:M790–M793.
   Google Scholar
• LYNN WA, COLENBOCK DT: Lipopolysaccharide antagonists. Immunol. Today (1992) 13:271–276.
   PubMedGoogle Scholar
• CHRIST WJ, OSAMU A, ROBIDOUX ALC et al: E5531 a pure endotoxin antagonist of high potency. Science (1995) 268:80–83.
   PubMed Web of Science ®Google Scholar
• KAWATA T, BRISTOL JR, ROSE JR et al.: Specific lipid A analogue which exhibits exclusive antagonism of endotoxin. In: Novel Therapeutic Strategies in the Treatment of Sepsis. Morrison D, Ryan J (Eds.), Marcel Dekker, Inc., New York, USA (1996):171–186.
   Google Scholar
• ASAI Y, NOZU Y, IKEUCHI T, NARAZAKI R, IWAMOTO K, WATANABE S: The effect of the lipid A analogue, E5531 on fever induced by endotoxin from Escherichia Pharm. Bull. (1999) 22(4):432–434.
   Google Scholar
• WASAN KM, STROBEL FW, PARROTT SC et al.: Lipopro-tein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels. Antimicrob. Agents Chemother. (1999) 43(102565–2564.
   Web of Science ®Google Scholar
• CAMENISCH TD, KOLLER BH, EARPS HS, MATSUSHIMA GK: A novel receptor tyrosine kinase, Mer, inhibits TNF-a production and lipopolysaccharide-induce endotoxic shock. J. Immunol. (1999) 162(6):3498–3503.
   PubMed Web of Science ®Google Scholar
• LIU SF, YE X, MALIK AB: Pyrrolidine dithiocarbamate prevents I-kappaB degradation and reduces microvas-cular injury induced by lip op olys accharide in multiple organs. Mol. Pharmacol. (1999) 55 (4):658–667.
   PubMed Web of Science ®Google Scholar
• BRIGHTBILL HD, LIBRATY DH, KRUTZIK SR et al Host defense mechanisms triggered by microbial through toll-like receptors. Science (1999) 285(5428)732–736.
   Google Scholar
• KAWAI T, ADACHI O, OGAWA T, TAKEDA K, AKIRA S: Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity (1999) 11(1):115–122.
   PubMed Web of Science ®Google Scholar
• KOPP EB, MEDZHITOV R: The Toll-receptor family andcontrol of innate immunity. Curr. Opin. Immunol. (1999) 11(1):13–18.
   PubMed Web of Science ®Google Scholar
• CARTER AB, MONICK MM, HUNNINGHAKE GW: Both Erkand p38 kinases are necessary for cytokine gene transcription. Am. J. Respir. Cell. Mol. Biol. (1999) 20 (4):751–758.
   PubMed Web of Science ®Google Scholar
• NICK-JA, AVDI NJ, GERWINS P, JOHNSON GL WORTHENGS: Activation of p38 mitogen activated protein kinase in human neutrophils by lipopolysaccharide. J. Immunol. (1996) 156(12):4867–4875.
   PubMed Web of Science ®Google Scholar
• VACCA A, FELLI MP, FARINA AR et al: Glucocorticoidreceptor-mediated suppression of the interleukin-2 gene expression through impairment of the co-operativity between nuclear factor of activated T-cells and AP-1 enhancer elements. J. Exp. Med. (1992) 175:637–646.
   PubMed Web of Science ®Google Scholar
• BOLLARET PE, CHARPENTIER C, LEVY B, DEBOUVERIE M,AUDIBERT G, LARCAN A: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Intensive Care Med. (1998) 26:645–650.
   Google Scholar
• BRIEGEL J, FORST H, HALLER Met al.: Stress doses ofhydrocortisone reverse hyperdynamic septic shock: a prospective, randomised, double-blind, single-centre study. Circ. Care Med. (1999) 27(4):723–732.
   Google Scholar
• HASKO G, KUHEL DG, NEMETH ZH et al. Inosine inhibits, inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J. Immunol. (2000) 164(2):1013–1019.
   PubMed Web of Science ®Google Scholar
• FELDMAN M, BONDESON J, BRENNAN FM, FOXWELL BM,MAINI RN: The rationale for the current boom in antiTNFa treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of antiTNFa and minimise hazards? Ann. Rheum. Dis. (1999) 58\(Suppl. 0:127–131.
   Google Scholar
• NEUNER P, KLOSNER G, SCHAUER E et al: Pentoxifyllinein vivo downregulates of IL-1B, IL-6, IL-8 and TNF a by human peripheral blood mononuclear cells. Immunology (1994) 83:262.
   PubMed Web of Science ®Google Scholar
• KRAKAUER T, STILES BG: Pentoxifylline inhibitssuperantigen-induced toxic shock and cytokine release. Clin. Diagn. Lab. Immunol. (1999) 6:594–598.
   PubMedGoogle Scholar
• ZHANG H, SPAPEN H, BENLABED M et al.: Pentoxifyllineimproves the tissue oxygen extraction capabilities during endotoxic shock. Shock (1994) 2:90–97.
   PubMed Web of Science ®Google Scholar
• DUNZENDORFER S, SCHRATZBERGER P, REINISCH N, KAHLER CM, WIEDERMANN CJ: Pentoxifylline differen-tially regulates migration and respiratory burst activity of the neutrophil. Ann. NY Acad. Sci. (1997) 832:330–340.
   PubMed Web of Science ®Google Scholar
• ARRIETA O, ORTIZ-REYES A, REMBAO D, CALVILLO M,RIVERA E, SOTELO J: Protective effect of pentoxifylline plus thalidomide against septic shock in mice. Int. J. Exp. Pathol. (1999) 80:11–16.
   PubMed Web of Science ®Google Scholar
• ZABEL P, SCHONHARTING MM, WOLTER DT et al: Pentoxifylline in endotoxaemia. Lancet (1989) 2:1474–1477.
   PubMed Web of Science ®Google Scholar
• STAUDINGER T, PRESTERL E, GRANINGER W et al: Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Intensive Care Med. (1996) 22:888–893.
   PubMed Web of Science ®Google Scholar
• SCHMIDT H, RUSH B, SIMONNIAN G et al.: Thalidomideinhibits TNF response and increases survival following endotoxin injection in rats. J. Surg. Res. (1996) 63:143–146.
   PubMed Web of Science ®Google Scholar
• PARMELY MJ, ZHOU WW, EDWARDS CK III, BORCHERDING DR, SILVERSTEIN R, MORRISON DC: Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumour necrosis factor-a production and protect mice against endotoxin challenge. J. Immunol. (1993) 151:389–396.
   PubMed Web of Science ®Google Scholar
• LANDGALE LA, MATER RV, WILSON L, POHLMAN TH, WILLIAMS JG, RICE CL: Liposome-encapsulated haemoglobin inhibits tumour necrosis factor release from rabbit alveolar macrophages by a posttranscrip-tional mechanism. J. Leukoc. Biol. (1992) 52:679–686.
   PubMedGoogle Scholar
• CARBARNS NJ, NEALE ML, STARK JM: Protective effect of an oestrogen against endotoxin-induced liver enzyme release. Int. J. Exp. Pathol. (1993) 74:309–315.
   PubMed Web of Science ®Google Scholar
• BEDROSIAN I, SOFIA RD, WOLFF SM, DINARELLO CA: Taurolidine, an analogue of the amino acid taurine, suppresses interleukin-1 and tumour necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine (1991) 3:568–575.
   PubMed Web of Science ®Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY R, COHN ZA, KAPLAN G: Thalidomide selectively inhibits tumour necrosis factor-a production by stimulated human monocytes. J. Exp. Med. (1991) 173:699–703.
   PubMed Web of Science ®Google Scholar
• SILVA AT, BAYSTON KF, COHEN J: Prophylactic and therapeutic effects of a monoclonal antibody to tumour necrosis factor-a in experimental Gram-negative shock. J. Infect. Dis. (1990) 162:421–427.
   PubMed Web of Science ®Google Scholar
• EXELY AR, COHEN J, BUURMAN WA et al.: Monoclonal antibody to TNF in severe septic shock [letter]. Lancet (1990) 335:1275–1257.
   Web of Science ®Google Scholar
• FISHER CJ, OPAL SM, DHAINAUT JF et al.: Influence of an antitumour necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Merl. (1993) 21:318–327.
   PubMed Web of Science ®Google Scholar
• VINCENT JL, BAKKER J, MAR CAUX G: Administration of antiTNE antibody improves left ventricular function in septic shock patients. Chest (1992) 101:810–815.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, WUNDERINK R, SILVERMAN H et al.: Efficacy and safety of monoclonal antibody to human tumour necrosis factor a in patients with sepsis syndrome: a randomised controlled, double-blind, multicenter clinical trial. JAMA (1995) 273:934–941.
   PubMed Web of Science ®Google Scholar
• COHEN J, CARLET J: INTERSEPT Study Group. INTERSEPT: an international multicenter, placebo-controlled trial of monoclonal antibody to human tumour necrosis factor-a, in patients with sepsis. Grit. Care Med. (1996) 24:1431–1440.
   Google Scholar
• FISHER CJ JR, AGOSTI JM, OPAL SM et al.: Treatment ofseptic shock with the tumour necrosis factor: Fc fusion protein. N Engl. J. Med. (1996) 334:1697–1702.
   PubMed Web of Science ®Google Scholar
• HASKO G, NEMETH ZH, VIZI ES, SALZMAN AL, SZABO C:An agonist of adenosine A3 receptors decreases interleukin-12 and interferon y production and prevents lethality in endotoxemic mice. Eur. J. Pharmacol. (1998) 358(3):261–268.
   PubMed Web of Science ®Google Scholar
• FISHER CJ, SLOTMAN GJ, OPAL SM et al.: Initial evalua-tion of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomised, open-label, placebo-controlled, multicenter trial. Crit. Care Med. (1994) 22:12–21.
   PubMed Web of Science ®Google Scholar
• FISHER CJ, DHAINAUT JF, OPAL SM et al.: Recombinanthuman interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA (1994) 271: 1836-1843.
   Google Scholar
• OPAL SM, FISHER CJ JR, DHAINAUT J-FA et al.: Confirma-tory interleukin-1 receptor antagonist trial in severe sepsis: a Phase III, randomised, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. (1997) 25:1115–1124.
   PubMed Web of Science ®Google Scholar
• CALANDRA T, ECHTENACHER B, ROY DL et al: Protec-tion from septic shock by neutralisation of macrophage migration inhibitory factor. Nat. Med. (2000) 6(2):164–170.
   PubMed Web of Science ®Google Scholar
• STEINHAUSER ML, HOGABOAM CM, LUKACS NW, STRIETER RM, KUNKEL SL: Multiple roles for IL-12 in a model of acute septic peritonitis. J. Immunol (1999) 162:5437–5443.
   PubMed Web of Science ®Google Scholar
• ZISMAN DA, KUNKEL SL, STREITER RM et al.:AntiInterleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia co/iperitoneal sepsis. Shock (1997) 8:349–356.
   PubMed Web of Science ®Google Scholar
• WANG H, BLOOM O, ZHANG M et al.: 11MG-1 as a latemediator of endotoxin lethality in mice. Science (1999) 285:248–251.
   PubMed Web of Science ®Google Scholar
• O'GRADY NP, TROPEA M, PREAS HL-2nd et al: Detectionof macrophage inflammatory protein (MIP)-1 a and ADP 113 during experimental endotoxemia and human sepsis. J. Infect. Dis. (1999) 179(1): 136–141.
   PubMed Web of Science ®Google Scholar
• KNAPP S, THALHAMMER F, LOCKER GJ et al.: Pronosticvalue of MIP-1 a, TGF 13 2, sELAM-1 and sVCAM-1 in patients with Gram-positive sepsis. Clin. Immunol. Immunopathol (1998) 87(2):139–144.
   PubMedGoogle Scholar
• WALLEY KR, LUKACS NW, STANDIFORD TJ, STRIETER RM,KUNKEL SL: Elevated levels of macrophage inflamma-tory protein 2 in several murine peritonitis increase neutrophil recruitment and mortality. Infect. Immun. (1997) 65 (9):3847–4851.
   PubMed Web of Science ®Google Scholar
• MATSUKAWA A, HOGABOAM CM, LUKACS NW, LINCOLNPM, STRIETER RM, KUNKEL SL: Endogenous monocyte chemoattractant protiein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross talk between MCP-1 and leucotriene B4. J. Immunol. (1999) 163(10:6148–6154.
   PubMedGoogle Scholar
• G RARD C, BRUYNS C, MARCHANT A et al.: Interleukin-10 reduces the release of tumour necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. (1993) 177:547–550.
   PubMed Web of Science ®Google Scholar
• MUCHAMUEL T, MENON S, PISACANE P, HOWARD MC,COCKAYNE DA: IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-a, IFN-y and 11-12 production. J. Immunol. (1997) 158:2898–2903.
   PubMed Web of Science ®Google Scholar
• DRMITRI MT, BENIGNI F, MEAZZA C et al: Protectiveeffect of ciliary neurotrophic factor (CNTF) in a model of endotoxic shock: action mechanisms and role of CNTF receptor a. J. Inflamm. (1998) 48:47–55.
   PubMedGoogle Scholar
• EREHACKER PQ, WAISMAN Y, NATANSON C et al.: Thecardiopulmonary effects of granulocyte colony stimulating factor in a canine model of bacterial peritonitis. J. Appl. Physiol. (1994) 77:2366–2373.
   PubMed Web of Science ®Google Scholar
• QUEZADO ZMN, NATANSON C, HOFFMAN WD et al:Granulocyte colony stimulating factor (GCS-F) treatment at the onset of E. co/i-peritonitis-induced septic shock in canines [abstract]. Am. J. Respir. Crit. Care Med. (1995) 151:A447.
   Web of Science ®Google Scholar
• WEISS M, GROSS WEEGE W, SCHMEIDER M et al: Enhancement of neutrophil function by in vivo fllgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J. Crit. Care (1995) 10:21–26.
   PubMed Web of Science ®Google Scholar
• KIRSCHFINK, M: Controlling the complement system in inflammation. Immunopharmacology (1997) 38:51–62.
   PubMed Web of Science ®Google Scholar
• SILVA, Al, COHEN J: Role of interferon-y in experimental Gram-negative sepsis. J. Infect. Dis. (1992) 166:331–335.
   PubMed Web of Science ®Google Scholar
• EVANS, T, CARPENTER A, SILVA A, COHEN J: Differential effects of monoclonal antibodies to tumour necrosis factor a and y interferon on induction of hepatic nitric oxide synthase in experimental Gram-negative sepsis. Infect. Immun. (1992) 60:4133–4139.
   PubMed Web of Science ®Google Scholar
• KIRSCHFINK M: Controlling the complement system in inflammation. Immunopharmacology (1997) 38:51–62.
   PubMed Web of Science ®Google Scholar
• STEVENS JH, O'HANLEY P, SHAPIRO JM et al: Effects of antiC5a antibodies on the adult respiratory distress syndrome in septic primates. J. Gin. Invest. (1986) 77:1812–1816.
   PubMed Web of Science ®Google Scholar
• JANSEN PM, EISELE B, DE JONG IW et al: Effect of Cl inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J. Immunol (1998) 160:475–484.
   PubMed Web of Science ®Google Scholar
• ZHANG H, BENLABED M, SPAPEN H et al: Prostaglandin El increases oxygen extraction capabilities in experi-mental sepsis. J. Surg. Res. (1994) 57:470–479.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, PARK YC, COVINGTON P et al.: Liposomal prostaglandin El in acute respiratory distress syndrome: a placebo-controlled, randomised, double-blind, multicenter clinical trial. Crit. Care Med. (1996) 24:10–15.
   PubMed Web of Science ®Google Scholar
• SONG SM, LU SM, WANG ZG, LIU JC, GUO SQ, LI Z: Subcellular membrane impairment and application of phospholipase A2 inhibitors in endotoxic shock. Injury (1999) 30(1):9–14.
   PubMed Web of Science ®Google Scholar
• YOKOTA Y, HANASAKI K, ONO T, NAKAZATO H, KOBAYASHI T, ARITA H: Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group HA sPLA2-independent mechanisms. Biochim. Biophys. Acta (1999) 1438(2):213–222.
   PubMed Web of Science ®Google Scholar
• MARSHALL LA, HALL RH, WINKLER JD et al: 5B203347, a inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock. J. Pharmacol. Exp. Ther. (1995) 274:1254–1262.
   PubMed Web of Science ®Google Scholar
• BAEK SH, YUN SS, KWON TK et al. The effects of two new, antagonists of secretory PLA2 on TNF, iNOS and COX-2 expression in activated macrophages. Shock (1999) 12(6):473–478
   PubMed Web of Science ®Google Scholar
• DE CASTRO CM, BUREAU MF, NAHORI MA, DUMAREY CH, VARGAFTING BB, BACHELET M: Modulation by dexamethasone of phospholipase A2 activates in endotoxemic guinea-pigs. J. Appl. Physiol. (1995) 79:1271–1277.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, WHEELER AP, RUSSELL JA et al: Effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl. J. Med. (1997) 336:912–918.
   PubMed Web of Science ®Google Scholar
• JESMOK G, GUNDEL R: Thromboxane, blocked swine as an experimental model of severe intravascular inflam-mation and septic shock. Shock (1995) 4(5):379–383.
   PubMed Web of Science ®Google Scholar
• YU M, TOMASA G: A double-blind, prospective, randomised trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit. Care Med. (1993) 21:1635–1642.
   PubMed Web of Science ®Google Scholar
• LEEMAN M, BOEYNAEMS JM, DEGAUTE JP et al. Administration of dazoxiben, a selective thromboxane synthetase inhibitor in patients with adult respiratory distress syndrome. Chest (1985) 87:726–730.
   PubMed Web of Science ®Google Scholar
• ZELTSMAN D, QUINN JV, MORES C, SLOTMAN GJ: Pathophysiologic plasma levels of leukotriene C4 in relation to the hemodynamic dysfunction and mediator release of graded bacteremia. Shock (1997) 7:282–287.
   PubMed Web of Science ®Google Scholar
• CAN C, CINAR MG, ULKER S, EVINC A, KOSAY S: Effects of MK886, a leukotriene biosynthesis inhibitor, in rabbit model of endotoxic shock. Eur. J. Pharmacol. (1998) 350:223–228.
   PubMed Web of Science ®Google Scholar
• ALPERT G, BALDWIN G, THOMPSON C et al.: Limulis antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock. J. Infect. Dis. (1992) 165:494–500.
   PubMed Web of Science ®Google Scholar
• BARSA D, MERLOS M, GIRAL M, FERRANDO R, GARCIA-RAFANELL J, FORN J: Effects of a new platelet-activating factor antagonist, UR-12670, on several endotoxic shock markers in rats. Drugs Exp. Clin. Res. (1997) 23:191–199.
   PubMedGoogle Scholar
• CLAVIJO LC, CARTER MG, MATHESON PJ et al: Platelet-activating factor and bacteremia-induced pulmonary hypertension. J. Surg. Res. (2000) 88:173–180.
   PubMed Web of Science ®Google Scholar
• FINK MP: Therapeutic options directed against platelet activating factor, eicosanoids and bradykinin in sepsis. J. Antimicrob. Chemother. (1998) 41 (Suppl. A):81–94.
   Google Scholar
• WILSON DD, DE GARAVILLA L, KUHN W, TOGO J, BURCH M,, STERANKA LR: D-Arg-[Hyp3-D-Phe7]-bradykinin antagonist reduce mortality in a rat model of endotoxic shock. Circ. Shock (1989) 27:93–101.
   PubMedGoogle Scholar
• WHALLEY ET, SOLOMON JA, MODAFFLERI DM, BONHAM KA, CHERONIS JC. CP-0127 a novel potent bradykinin increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl. (1992) 38:413–420.
   Google Scholar
• MARUO K, AKAIKE T, ONO T, MAEDA H: Involvement of bradykinin generation in intravascular dissemination of Vibro vulnificus and prevention of invasion by a bradykinin antagonist. Infect. Immun. (1998) 66:866–869.
   PubMed Web of Science ®Google Scholar
• FELETOU M, JAMONNEAU I, GERMAIN M et al.: Bradyki-nin B2 receptor involvement in rabbit and murine models of septic shock. J. Cardiovasc. Pharmacol. (1996) 27:500–507.
   PubMed Web of Science ®Google Scholar
• SIEBECK M, SPANNAGL E, SCHORR M et al: Effect of combined B1 and B2 kin receptor blockade in porcine endotoxin shock. Immunopharmacology (1996) 33:81–84.
   PubMedGoogle Scholar
• FELETOU M, LONCHAMPT M, ROBINEAU P et al.: Effect of the bradykinin B2 receptor antagonist S 16118 in different in vivo animal model of inflammation. J. Pharmacol. Exp. Ther. (1995) 273:1078–1084.
   PubMed Web of Science ®Google Scholar
• SAKAI A: Protection against septic shock in mice with SJC13, an azaindolidine derivative that is a cell adhesion molecule inhibitor. In/lam. Res. (1996) 45:448–451.
   PubMed Web of Science ®Google Scholar
• SYMEONIDES S, BLAK RA: Nitric oxide in the pathogenic of sepsis. Infect. Dis. Clin. North Am. (1999) 13(2)449–463.
   Google Scholar
• HOBBS AJ, HIGGS A, MONCADA S: Inhibition of nitric oxide synthase as a potential therapeutic target. Ann. Rev Pharmacol. Toxicol. (1999) 39:191–220.
   PubMed Web of Science ®Google Scholar
• MULDER MF, LAMBALGEN AA, HUISMAN E et al.: Protec-tive role of NO in the regional hemodynamic changes during acute endotoxemia in rats. Am. J. Physiol. (1994) 226:H1558–564.
   Google Scholar
• MEYER J, LENTZ CW, STOTHERT JC et al.: Effects of nitric oxide synthesis inhibition in hyperdynamic endotoxemia. Crit. Care Med. (1994) 22:306–312.
   PubMed Web of Science ®Google Scholar
• KIEHL MG, OSTERMANN H, MEYER J, KIENAST J: Nitric oxide synthase inhibition by L-NAME in leukocy-topenic patients with severe septic shock. Intensive Care Med. (1997) 23:561–566 /
   Google Scholar
• KILBOURN R: Nitric oxide synthase inhibitors - a mechanism-based treatment of septic shock. Crit. Care Med. (1999) 27:857–858.
   PubMed Web of Science ®Google Scholar
• LOCKER GJ, BURGMANN H, STAUDINGER T, KNAPP S, LACZIKA KF, FRASS M: Fatal effects of L-NMMA? Crit. Care Med. (1996) 24:1930.
   Google Scholar
• GROVER R, ZACCARDELLI D, COLICE G, GUNTUPALLI K, WATSON D, VINCENT JL: An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-t-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome Interna-tional Septic Shock Study Group. Crit. Care Med. (1999) 27 (5):913–922.
   Google Scholar
• HUSSEIN Z, BEERAHEE M, GROVER R et al.: Pharmacoki-netics of the nitric oxide synthase inhibitor t-NG-methylarginine hydrochoride in patients with septic shock. Glaxo Wellcome International Septic Shock Group. Clin. Pharmacol Ther. (1999) 65(0:1–9.
   PubMedGoogle Scholar
• KRECIC-SHEPARD ME, SHEPARD DR, MULLET D, APSELOFF G, WEISBRODE SE, GERBER N: Gallium nitrate suppresses the production of nitric oxide and liver damage in a murine model of LPS-induced septic shock. Life ScL (1999) 65(13)1359–1371.
   Google Scholar
• STEEGE JC, FORGET PP, BURMAN WA. Oral spermine administration inhibits nitric oxide-mediated intestinal damage and levels of systemic inflammatory mediators in a mouse endotoxin model. Shock (1999) 11:115–119.
   Google Scholar
• LEVY B, VALTIER M, DE CHILLOU C, BOLLAERT PE, CANE D, MALLIE JP: Beneficial effects of t-canavanine, a selective inhibitor of inducible nitric oxide synthase, on lactate metabolism and muscle high energy phosphate during endotoxic shock in rats. Shock (1999) 11:98–103.
   PubMed Web of Science ®Google Scholar
• ZANETTI G, HEUMANN D, GERAIN J et al.: Cytokine production after iv. or peritoneal Gram-negative bacterial challenge in mice: comparative protective efficacy of antibodies to tumour necrosis factor-a and to lipopolysaccharide. j Immunol. (1992) 148:1890–1897.
   Google Scholar
• GACHOT E, BDOS JP, VEBER B, WOLFF M, R GINER B: Short-term effects of methylene blue on haemody-namics and gas exchange in humans with septic shock. Intensive Care Med. (1995) 21:1027–1031.
   PubMed Web of Science ®Google Scholar
• GROVER R, ZACCARDELLI D, COLICE G, GUNTUPALLI K, WATSON D, VINCENT JL: An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-t-arginine hydrochloride (546C88), in patients with septic shock. Crit. Care Med. (1999) 27:913–922.
   PubMed Web of Science ®Google Scholar
• ANDRESEN M, DOUGNAC A, D0AZ 0 et al: Use of methylene blue in patients with refractory septic shock: impact on haemodynamics and gas exchange. Crit. Care (1998) 13(4):164–168.
   Web of Science ®Google Scholar
• WU CC, CHEN SJ, SZABO C, THIEMERMANN C, VANE JR: Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br. J. Pharmacol. (1 9 9 5) 114(8):1666–1672.
   Google Scholar
• WOLFARD A, KASZAKI J, SZABO C, SZALAY L, NAGY S, BOROS M: Prevention of early myocardial depression in hyperdynamic endotoxemia in dogs. Shock (2000) 13(1):46–51.
   PubMed Web of Science ®Google Scholar
• COCHRAN JB, GENOVESE F, OGURA S, TETI G, COOK JA: Effect of nitric oxide donors and nitric oxide synthase inhibitors in neonatal rat endotoxic shock. Biochem. Pharmacol. (1999) 58(4) 687–691.
   PubMed Web of Science ®Google Scholar
• DICKINSON E, TUNCER R, NADLER E, BOYLE P, ALBER S, WATKINS S: NOX, a novel nitric oxide scavenger, reduces bacterial translocation in rats after endotoxin challenge. Am. J. Physic)]. (1999) 277(6 Pt 1):G1281–287.
   Google Scholar
• BONE HG, FISCHER SR, SCHENARTS PJ eta].: Continuous infusion of pyridoxalated hemoglobin polyoxyeth-ylene conjugate in hyperdynamic septic sheep. Shock (1998) 10:69–76.
   Google Scholar
• REINHART K, SPIES CD, MEIER-HELLMANN A et al.: N-acetylcysteine preserves oxygen consumption and gastric mucosal pH during hyperoxic ventilation. Am. Respir. Grit. Care Med. (1995) 151:773–779.
   PubMed Web of Science ®Google Scholar
• PEAKE SL, MORAN JL, LEPPARD PL: N-acetyl-t-cysteine depresses cardiac performance in patients with septic shock. Crit. Care Med. (1996) 24:1302–1310.
   PubMed Web of Science ®Google Scholar
• SPAPEN H, ZHANG H, DEMANET C, VLEMINCKX W, VINCET JL, HUYGHENS L: Does N-acetyl-t-cysteine influence cytokine response during early human septic shock? Chest (1998) 113: 1616-1624.
   Google Scholar
• GALLEY HF, HOWDLE PD, WALKER BE, WEBSTER NR: The effect of iv. anti-oxidants in patients with septic shock. Free Radic. Biol. Merl. (1997) 23:768–774.
   PubMed Web of Science ®Google Scholar
• LAUZURIA P, MARTINEZ-MARTINEZ S, MARAZUELA M et Pyrrolidine dithiocarbamate protects mice from lethal shock induced by LPS or TNF-a. Eur. J. Immunol. (1999) 29:1890–1900.
   PubMed Web of Science ®Google Scholar
• MEISNER M, SCHMIDT J, SCHYWALSKY M, TSCHAIKOWSKY K: Influence of pyrrolide dithiocarba-mate on the inflammatory response in macrophages and mouse endotoxin shock. Int. J. Immunopharmacol. (2000) 22(1)83–90.
   Google Scholar
• DELLA RAGIONE F, CUCCIOLLA V, BORRIELLO A et al: Pyrrolidine dithiocarbamate induces apoptosis by a cytochrome c-dependent mechanism. Biochem. Biophys. Res. Commun. (2000) 268(3)942–946.
   Google Scholar
• NEMETH ZH, HASKO G, VIZI ES: Pyrrolidine dithiocar-bamate augments IL-10, inhibits TNF-a, MIP 1 a, IL-12 and nitric oxide production and protects from the lethal effect of endotoxin. Shock (1998) 10(1):49–53.
   PubMed Web of Science ®Google Scholar
• ALTAVILLA D, SQUADRITO F, SERRANO M eta].: Inhibi-tion of tumour necrosis factor and reversal of endotoxin-induced shock by U-83836E, a 'second generation' lazaroid in rats. Br J.Pharmacol.(1998) 124:1293–1299.
   Google Scholar
• ATAVILLA D, SQUADRITO F, CAMPO GM, SQUADRITO G, ARLOTTA M, URNA G: The lazaroid, U-74389G, inhibits inducible nitric oxide synthase activity, reverses vascular failure and protects against endotoxin shock. Eur. J. Pharmacol. (1999) 369:49–55.
   PubMed Web of Science ®Google Scholar
• GONZALEZ PK, ZHUANG J, DICTROW SR et al.: EUK-8, a synthetic superoxide dismutase and catalase mimetic, ameliorates acute lung injury in endotoxemic swine. J. Pharmacol. Exp. Ther. (1995) 275(2):798–806.
   PubMed Web of Science ®Google Scholar
• SCHILLER HJ, REILLY PM, BULKLEY GB: Anti-oxidant therapy. Grit. Care Merl. (1993) 21:S92–102.
   PubMed Web of Science ®Google Scholar
• KONG CW, TSAI K, CHIN JH, CHAN WL, HONG CY: Magnolol attenuates peroxidative damage and improves survival of rats with sepsis. Shock (2000) 13:24–28.
   PubMed Web of Science ®Google Scholar
• VASQUEZ Y, WILLIAMS CH, HARDAWAY RM: Effect of urokinase on disseminated intravascular coagulation. Appl. Physiol. (1998) 85:1421–1428.
   PubMed Web of Science ®Google Scholar
• FOURRIER F, CHOPIN C, HUART J: Double-blind placebo-controlled trial of antithrombin III concen-trates in septic shock with disseminated intravascular coagulation. Chest (1993) 104:882–888.
   PubMed Web of Science ®Google Scholar
• BALK R, EMERSON T, FOURRIER F et al.: Therapeutic use of antithrombin concentrate in sepsis. Semin. Thromb. HemosL (1998) 24:183–194.
   PubMed Web of Science ®Google Scholar
• GIEBLER R, SCHMIDT U, KOCH S, PETERS J, SCHERER R: Combined antithrombin III and Cl-esterase inhibitor treatment decrease intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coil endotoxin. Grit. Care Med. (1999) 27:597–604.
   PubMed Web of Science ®Google Scholar
• INGHORN D, HOFFMANN JN, HARTL WH, MUHLBAYER D, JOCHUM M: Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock (1997) 8:328–334.
   PubMed Web of Science ®Google Scholar
• GOLDFARB RD, GLOCKD, JOHNSON K et al. Random- ised,, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Shock (1998) 10(4):258.
   PubMed Web of Science ®Google Scholar
• ERIKSSON M, LARSSON A, SALDEEN T, MATTSSON C: Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemody-namic and renal dysfunctions in the pig. Throm. Haemost. (1998) 80(6):1022–1026.
   PubMed Web of Science ®Google Scholar
• DEMARIA A, CRAVEN DE, HEFLENNAN JJ, MELNTOSH TK, GRINDLINGER GA, MCCABE WR: Naloxone versus placebo in treatment of septic shock. Lancet (1985) 1:1363–1365.
   PubMed Web of Science ®Google Scholar
• LAW WR, MOURELATOS MG, KRAHMER R, DZIKI AJ, LYNCH WH, FERGUSON JL: Effects of phentolamine or yohimbine on naloxone's actions during endotoxin shock in rats. Shock (1997) 7:217–224.
   PubMed Web of Science ®Google Scholar
• OLDNER A, WANECEK M, GOINY M et al.: The endothelin receptor antagonist bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis in porcine endotoxin shock. Gut (1998) 42:696–702.
   PubMed Web of Science ®Google Scholar
• MITAKA C, HIRATA Y, YOKOYAMA K, NAGURA T, TSUNODA Y, AMAHA K: Improvement of renal dysfunc-tion in dogs with endotoxemia by a nonselective endothelin receptor antagonist. Crit. Care Med. (1999) 27:146–153.
   PubMed Web of Science ®Google Scholar
• WANECEK M, RUDEHILL A, HEMSEN A, LUNDBEREG JM, WEITZBERG E: The endothelin receptor antagonist bosentan, in combination with the cyclooxygenase inhibitor, diclofenac, counteracts pulmonary hypertension in porcine endotoxin shock. Grit. Care Med. (1997) 25:848–857.
   PubMed Web of Science ®Google Scholar
• WANECEK M, OLDNER A, RUDEHILL A, SOLLEVI A, ALVING K, WEITZBERG E: Cardiopulmonary dysfunc-tion during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan. Shock (1997) 7:364–370.
   PubMed Web of Science ®Google Scholar
• BOLDT J, PAPSDORF M, KUMLE B, PIPERS, HEMPELMANN G: Influence of angiotensin-converting enzyme inhibitor enalaprilat on endothelial-derived substances in the critically ill. Crit. Care Med. (1998) 26:1663–1670.
   PubMed Web of Science ®Google Scholar
• MALAY MB, ASHTON RC JR, LANDRY DW, TOWNSEND RN: Low-dose vasopressin in the treatment of vasodila-tory septic shock. J. Trauma (1999) 47:699–703.
   PubMed Web of Science ®Google Scholar
• SIEBECK M, SPANNAGL M, HOFFMANN H, FINK E: Effects of protease inhibitors in experimental septic shock. Agents Actions Suppl (1992) 38 (Pt3):421–427.
   Google Scholar
• TANI T, AOKI H, YOSHIOKA T, LIN KJ, KODAMA M: Treatment of septic shock with a protease inhibitor in a canine model: a prospective, randomised, controlled trial. Crit. Care Med. (1993) 21:925–930.
   PubMed Web of Science ®Google Scholar
• GEHA RS, ROSEN FS: Intravenous immunoglobulin therapy. In: Therapeutic Immunology. Austen KF, Burakoff SJ, Rosen FS, Strom TB, (Eds.), Blackwell Science, Cambridge, USA (1996):280–296.
   Google Scholar
• YU Z, LENNON VA: Mechanism of iv. immune globulin therapy in antibody-mediated autoimmune diseases. N Engl. J. Med. (1999) 340:227–228.
   Google Scholar
• WERDAN K: Supplemental immunoglobulins in sepsis. Clin. Chem. Lab. Med. (1999) 37:341–349.
   PubMed Web of Science ®Google Scholar
• MAESTRONI GJ: Melatonin as a therapeutic agent in experimental endotoxic shock. J. Pineal Res. (1996) 20(2)84–89.
   Google Scholar
• BEN-NATHAN D, PADGETT DA, LORIA RM: Androstene-diol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysac-caride toxicity. J. Med. Microbiol. (1999) 48:425–431.
   PubMed Web of Science ®Google Scholar
• HUANG YCT, NOZIK ES, PIANTADOSI CA: Super oxide dismutase potentates platelet-activating factor-induced injury in perfused lung. Am. J. Physiol. (1994) 266:L246–254.
   Google Scholar
• OPAL SM, CROSS AS, JHUNG JW et al.: Potential hazards of combination immunotherapy in the treatment of experimental septic shock. J. Infect. Dis. (1996) 173:1415–1421.
   PubMed Web of Science ®Google Scholar
• PERITI P, MAZZEI T: Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review. J. Chemother. (1998) 10:427–448.
   PubMed Web of Science ®Google Scholar
• SUFFREDINI AF, REDA D, BANKS SM et al: Effects of recombinant dimeric TNF receptor on human inflam-matory responses following iv. endotoxin administra-tion. J. Immunol. (1995) 155:5038–5045.
   Google Scholar
• BAGBY GJ, PLESSALA KJ, WILSON LA et al.: Divergent efficacy of antibody to tumour necrosis factor-a in intravascular and peritonitis models of sepsis. J. Infect. Dis. (1991) 163:83–88.
   PubMed Web of Science ®Google Scholar
• AVONTUUR JA, TUTEIN-NOLTHENIUS RP, VAN BODEGOM JW, BRUINING HA: Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit. Care Med. (1998) 26:660–667.
   PubMed Web of Science ®Google Scholar
• STUBER F, PETERSEN M, BOKELMAN F: A genomic polymorphism within the tumour necrosis factor locus influences plasma tumour necrosis factor-a concentrations and outcome of patients with severe sepsis. Grit. Care Med. (1996) 24:381–384.
   PubMed Web of Science ®Google Scholar
• PIPER RD, COOK DEBORAH JC, BONE R, SIBBALD W. Introducing Critical Appraisal to studies of animal model investigating novel therapies in sepsis. Grit. Care Med. (1996) 24:2059–2070.
   PubMed Web of Science ®Google Scholar
• TEPLICK R, RUBIN R: Therapy of sepsis: why have we made such little progress? Crit. Care Med. (1999) 27:1682–1683.
   Google Scholar